On April 1, 2025 CuraCell reported the company will present clinical outcomes of patients treated with our Tumor Infiltrating Lymphocytes (TIL)-based therapy this spring at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting and the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, both taking place in the United States. All patients treated, on a patient-named basis, were diagnosed with late-stage solid tumors and refractory to all conventional therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations mark a significant milestone for our team as we share important data highlighting the potential of our TIL-product CC-38 to address the unmet medical need in cold solid tumors.
"We look forward to connecting with the scientific and clinical community during these events and continuing the conversation on advancing durable, personalized cancer immunotherapy." said Dr. Lucas Arruda, CSO of CuraCell.
(Press release, CuraCell, APR 1, 2025, View Source [SID1234661186])